CA3080087A1 - Multivalent feline vaccine - Google Patents

Multivalent feline vaccine Download PDF

Info

Publication number
CA3080087A1
CA3080087A1 CA3080087A CA3080087A CA3080087A1 CA 3080087 A1 CA3080087 A1 CA 3080087A1 CA 3080087 A CA3080087 A CA 3080087A CA 3080087 A CA3080087 A CA 3080087A CA 3080087 A1 CA3080087 A1 CA 3080087A1
Authority
CA
Canada
Prior art keywords
fcv
feline
capsid protein
vaccine
antigenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3080087A
Other languages
English (en)
French (fr)
Inventor
Zhichang Xu
Rhonda Lafleur
Ian Tarpey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CA3080087A1 publication Critical patent/CA3080087A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3080087A 2017-12-15 2018-11-05 Multivalent feline vaccine Pending CA3080087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599401P 2017-12-15 2017-12-15
US62/599,401 2017-12-15
PCT/EP2018/080106 WO2019115090A1 (en) 2017-12-15 2018-11-05 Multivalent feline vaccine

Publications (1)

Publication Number Publication Date
CA3080087A1 true CA3080087A1 (en) 2019-06-20

Family

ID=64316488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3080087A Pending CA3080087A1 (en) 2017-12-15 2018-11-05 Multivalent feline vaccine

Country Status (4)

Country Link
JP (3) JP7427585B2 (enExample)
AU (2) AU2018383915B9 (enExample)
CA (1) CA3080087A1 (enExample)
WO (1) WO2019115090A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421790B2 (en) * 2015-12-23 2019-09-24 Intervet, Inc. Feline calicivirus vaccine
EP4149532A1 (en) 2020-05-11 2023-03-22 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
CA3198118A1 (en) 2020-11-12 2022-05-19 Martijn Alexander LANGEREIS Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066568A2 (en) * 2000-03-09 2001-09-13 Heska Corporation Use of recombinant antigens to determine the immune status of an animal
DE60130569D1 (de) 2000-08-29 2007-10-31 Wyeth Corp Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
US7309495B2 (en) 2003-03-14 2007-12-18 The Regents Of The University Of California Hemorrhagic feline calicivirus
EP1751289B1 (en) * 2004-05-18 2009-01-14 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US10421790B2 (en) 2015-12-23 2019-09-24 Intervet, Inc. Feline calicivirus vaccine
US10411152B2 (en) * 2016-06-27 2019-09-10 Merlin Solar Technologies, Inc. Solar cell bonding
CA3080427A1 (en) * 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine
AU2018380582B2 (en) * 2017-12-08 2025-08-14 Intervet International B.V. Feline calicivirus vaccine

Also Published As

Publication number Publication date
AU2022209359A1 (en) 2022-09-29
WO2019115090A1 (en) 2019-06-20
JP2021506746A (ja) 2021-02-22
JP2025170230A (ja) 2025-11-18
JP2023179547A (ja) 2023-12-19
AU2018383915B2 (en) 2023-05-25
AU2018383915A1 (en) 2020-05-14
AU2018383915B9 (en) 2023-06-01
JP7742695B2 (ja) 2025-09-22
JP7427585B2 (ja) 2024-02-05
AU2022209359B2 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
JP7742695B2 (ja) 多価ネコワクチン
AU2025230686A1 (en) Feline leukemia virus vaccine
JP7721604B2 (ja) ネコカリシウイルスワクチン
AU2018360288B2 (en) Rabies virus vaccine
US11730809B2 (en) Multivalent feline vaccine
US20240398934A1 (en) Feline leukemia virus vaccine
RU2797538C2 (ru) Поливалентная вакцина для животных семейства кошачьих
US20240269259A1 (en) Rabies virus vaccine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231106

EEER Examination request

Effective date: 20231106